Physician profile
Kara Tipsword
NPI 1689363509
$623.52
in general payments reported to CMS, 2019-2025
15 companies · $536 in 2025
The $536 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $33.38 · 2024: $54.23 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $97.20 | 2025 | Fanapt |
| Abbvie INC. | $91.21 | 2024-2025 | |
| Janssen Biotech, INC. | $86.87 | 2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $84.55 | 2025 | Voquezna |
| Novo Nordisk INC | $47.62 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $37.13 | 2025 | Entyvio |
| Ardelyx, INC. | $33.92 | 2025 | Ibsrela |
| Neurocrine Biosciences, INC. | $21.00 | 2025 | |
| Exact Sciences Corporation | $20.15 | 2025 | Cologuard Collection Kit |
| Qol Medical, LLC | $20.08 | 2025 | Sucraid |
| Astrazeneca Pharmaceuticals LP | $19.96 | 2024 | Breztri |
| Dexcom, INC. | $18.37 | 2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $16.18 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.01 | 2023 | Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.27 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Tipsword listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.